Locations:
SearchAdvertisement
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Long-term relationship building and engagement key to gaining community trust
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer
Breaking through barriers in cancer care
The cornerstone of a successful doctor-patient relationship
Dr. Aaron Gerds argues for more balance in safety reporting
Cancers that predominantly affect Black patients and cancers with higher mortality rates receive less funding
Study shows encouraging safety results in rare type of adult brain cancer
Advertisement
Advertisement